In a nutshell This study investigated the overall survival rates of people with breast cancer who were treated with either palbociclib (Ibrance) plus fulvestrant (Faslodex), or just fulvestrant. The study found that the patients who received both palbociclib and fulvestrant had a longer overall survival compared to the group who only received...
Read More
In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...
Read More
In a nutshell This trial is examining the effectiveness of tesetaxel plus a reduced dose of capecitabine for hormone receptor (HR) positive/HER2 negative advanced breast cancer. The main outcome to be measured will be progression free survival (time from treatment until disease progression). The details Breast cancer is classified into...
Read More
In a nutshell This study examined if the presence of certain genes had an effect on endocrine (hormone) treatment alone compared to chemoendocrine (chemotherapy and hormone) treatment for breast cancer. The study concluded that endocrine and chemoendocrine had the same effectiveness in women with certain genetic factors. Some background Breast cancer...
Read More
In a nutshell This study aimed to find out if the breast cancer treatment palbociclib (Ibrance) works better alone, or in combination with other endocrine therapies (drugs which act on hormone receptors) used to treat estrogen receptor positive (ER+ – a hormone receptor found on the tumor) breast cancer. The authors found that treating women...
Read MoreIn a nutshell This study aimed to compare anastrozole (Arimidex) and tamoxifen (Nolvadex) in the treatment of breast cancer. This study concluded that anastrozole is effective in the treatment of breast cancer. Some background Breast cancer is classified into different subtypes depending on the presence or absence...
Read More
In a nutshell This study aimed to find out if endocrine therapy (ET) is best used alone or with targeted therapy in the treatment of hormone positive, HER2 negative advanced breast cancer. The study found that patients who used ET and targeted therapy together experienced a better quality of life in some regards compared to ET used alone. Some...
Read More
In a nutshell This study aimed to compare the benefits of taking letrozole for 2.5 years versus 5 years in post-menopausal patients with early stage breast cancer. This study found no benefit of five years extended therapy with letrozole compared to 2.5 years, after an initial five years of hormone therapy. Some background Breast...
Read More
In a nutshell This study aimed to evaluate the effectiveness and safety of endocrine therapy, with or without targeted therapy, for patients with advanced metastatic breast cancer. This study concluded that the use of endocrine therapy and targeted therapy is safe for use in patients over 65. Some background There are several treatment...
Read More
In a nutshell This study aimed to determine the effectiveness and safety of ribociclib (Kisqali) combined with a non-steroidal aromatase inhibitor in elderly patients with hormone receptor positive and HER-2 negative breast cancer. This study concluded that ribociclib improved progression free survival and was relatively safe to use...
Read MoreIn a nutshell This phase 3 trial aims to evaluate the effectiveness of palbociclib (Ibrance) in combination with standard treatments for HER2 positive breast cancer. The main outcome to be investigated is progression free survival. This trial is taking place in Alabama, Illinois, Iowa, Nebraska and Oklahoma in the United States. The details...
Read More
In a nutshell This study aimed to compare abemaciclib (Verzenio) to a placebo treatment (substance with no active effect). The study concluded that it increased progression-free survival and was relatively safe to use as a first-line treatment. Some background There are several treatment options for hormone positive, HER-2 negative...
Read More
